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Background:We assessed the clinical validity of circulating tumor cell (CTC) quantifi-
cation for prognostication of patients with advanced non-small cell lung cancer
(NSCLC) by undertaking a European pooled analysis of individual patient data. This is
the largest study of its kind and the first to examine between-centre heterogeneity of
CTC identification in NSCLC.
Methods:Nine European NSCLC CTC centers were asked to provide reported/unre-
ported anonymised data for patients with advanced NSCLC who participated in
CellSearch CTC studies from January 2003 -March 2017.We used Cox regression
models, stratified by centre, to establish the association between CTC count and sur-
vival. We assessed the added value of CTCs to prognostic clinico-pathological models
using likelihood ratio (LR) statistics and c-indices.
Results: Seven out of nine eligible centers provided data for 550 eligible patients,
including 209 patients whose prognostic information was previously unpublished.
CTC counts of 2 and5 per 75mLwere associated with reduced progression-free
survival (2 CTCs: HR 1.72, p< 0001;5 CTCs: HR 2.21, p< 0001) and overall sur-
vival (2 CTCs: HR 218, p< 0001;5 CTCs: HR 275, p< 0001), respectively.
Survival prediction was significantly improved by addition of baseline CTC count to
LR clinico-pathological models (log-transformed CTCs p< 00001;2 CTCs
p< 00001;5 CTCs p< 00001), while more moderate improvements were observed
with the use of c-index models. There was minor evidence of between-center heteroge-
neity in the effect on PFS, but not OS.No difference in CTC profile was observed
between key NSCLCmolecular subsets such as EGFR, ALK, and KRAS.
Conclusions: These data confirm CTCs as an independent prognostic indicator of
progression-free survival and overall survival in advanced NSCLC. CTC count
improves prognostication when added to full clinico-pathological predictive models.
2 CTCs is an appropriate cutoff to move towards establishing clinical utility.
Legal entity responsible for the study: The authors.
Funding:Has not received any funding.
Disclosure: C.R. Lindsay: Institutional funding for an ongoing phase II trial for which I
am PI; Supported by Roche as part of an ESMO translational fellowship awarded in
2014-2016. F.H. Blackhall: Grants: AstraZeneca, Novartis, Pfizer, Amgen, BMS;
Consultancy fees: Cell Medica, MSD; Speaker bureau: BI; Advisory board work:
Regeneron, Medivation, AbbVie, Takeda, Roche, Ibsen. M.G. Krebs: Advisory board:
J&J. L. Terstappen: Inventor on a number of US patents related to CellSearch, rights of
which assigned to Johnson&Johnson, CellSearch kits obtained from Johnson&Johnson
through a collaborative agreement with theMCBP. J-C. Soria: Consultancy fees: AZ,
Astex, Clovis, GSK, GamaMabs, Lilly, MSD,Mission Therapeutics, Merus, Pfizer,
PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, Takeda; Full
time employee: MedImmune; Shareholder: AZ, Gritstone. All other authors have
declared no conflicts of interest.
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patients induces peripheral effector CD8 T cell proliferation that could
be prone for treatment with checkpoint inhibitors
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Background: Checkpoint inhibitors targeting programmed death receptor (PD)-1 or
PD-ligand 1 (PD-L1) became the cornerstone in the treatment of advanced NSCLC.
Several phase III trials showed a better overall survival by treating with combination
chemotherapy and checkpoint inhibition, suggesting that addition of chemotherapy
increased the response to checkpoint inhibitors. Recently, peripheral blood biomarkers
such as Ki67þPD-1þCD8 cells were found to be predictive for clinical outcome with
PD-1 treatment. Knowingmore about immunemodulatory capacities of chemother-
apy can help us to design better treatment strategies. We investigated the immune-
modulatory effects of paclitaxel/carboplatin/bevacizumab (PCB), focusing on known
immune populations associated with response to checkpoint inhibitors in peripheral
blood.
Methods: In the NVALT 12 study, 223 patients with advanced NSCLC were enrolled to
receive PCB, with or without nitroglycerin patch. At baseline and after the first and sec-
ond treatment cycle, peripheral blood was drawn. By flow cytometry, the proportions
of T cells and several subsets and co-inhibitory receptors of these, B cells andmonocytes
were determined.
Results: 6 weeks after starting treatment with PCB, the proportions of T cells were sig-
nificantly increased compared to baseline values. Within the T cells subsets, prolifera-
tion of CD4 T cells remained stable whereas proliferation of CD8 T cells (Ki67þ) were
significantly increased. The proliferating Ki67þCD8 T cells expresses more PD-1 com-
pared to non-proliferating CD8 T cells. However, patients with>2 fold increased pro-
liferation of T cells did not show a better outcome.
Conclusions: Paclitaxel/ carboplatin/ bevacizumab induces proliferation of CD8 T cells
which expresses more co-inhibitory checkpoint molecules. Progression free and overall
survival was unchanged by this increase on its own, showing the rationale to combine
PCB with checkpoint inhibition in lung cancer, as used in Impower 150.
Clinical trial identification:NCT01171170.
Legal entity responsible for the study: The authors.
Funding:NVALT.
Disclosure:D. Dumoulin: Speakers fee: BMS, Roche, Pfizer, Novartis. A-M.C.
Dingemans: Advisory boards, lectures: Roche, Eli Lilly, Boehringer Ingelheim,
AstraZeneca, Pfizer, BMS, Amgen, Novartis, MSD, Takeda (honoraria to institution).
J.G. Aerts: Advisory boards: BMS, Boehringer Ingelheim,MSD, AstraZeneca, Eli Lilly,
Takeda, Amphera; Stock owner: Amphera B.V. All other authors have declared no con-
flicts of interest.
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Background: iSenescence is a remodeling of immune functions with a multifactorial
etiology (i.e. aging, chronic inflammation, cancer). Although the absence of CD28 and
the expression of CD57 and KLRG1 on circulating T-lymphocytes are hallmarks of
iSenescence, the characterization of such phenotype in aNSCLC pts and the correlation
with clinical characteristics and benefit from IO or PCT are currently unknown.
Methods: A senescent immune phenotype (SIP) defined as % of circulating
CD8þCD28-CD57þKLRG1þ T-lymphocytes was assessed by flow cytometry (FC) on
fresh blood from aNSCLC pts treated with IO or PCT in a single institution. A log-rank
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